NICE ‘yes’ to Imnovid in the fight against the biggest blood cancer killer in the UK
Pomalidomide available to people in England immediately via the Cancer Drugs Fund.
Today, the National Institute for Health and Care Excellence (NICE) has recommended the use of pomalidomide, in combination with dexamethasone, via the NHS for people in England with relapsed and refractory multiple myeloma (RRMM). Specifically, the treatment is recommended for adults at third or subsequent relapse following three previous treatments including both Revlimid (lenalidomide) and bortezomib. This decision means that pomalidomide is now accessible to all eligible patients on the health service throughout the UK, and will be available to people in England immediately via the Cancer Drugs Fund.
Pomalidomide works by both directly targeting myeloma cells and utilising the body’s immune system to help find and fight the cancer. In clinical studies, patients who had received at least two prior treatment regimens benefitted from an overall survival increase when treated with pomalidomide, compared to those receiving high-dose dexamethasone alone (13.1 months vs 8.1 months).
Dr Kevin Boyd, Consultant Haematologist at The Royal Marsden Hospital, London comments: “Today’s news will be welcomed by both the clinical community and the multiple myeloma patients we treat. For most patients, multiple myeloma is an incurable blood cancer which requires a different treatment option at every stage of disease. Pomalidomide is an important treatment for people affected by late stage multiple myeloma; we know that it is an effective medicine and can be taken by patients long term. It is very reassuring that the medicine will be available to patients as the only NICE approved treatment at this stage of the disease.”
Eric Low, Chief Executive at Myeloma UK comments: “This is brilliant news for myeloma patients in England, who have been unable to access pomalidomide on the NHS since September 2015, when it was delisted from the Cancer Drugs Fund. Pomalidomide is an effective treatment which will fill a major gap in the treatment pathway for patients at third relapse and beyond. We are really pleased that through effective collaboration between Celgene, Myeloma UK and NICE, it has resulted in approval of this treatment.”
Commenting on the NICE decision, Dr Adrian Kilcoyne, Medical Director at Celgene UK & Ireland, said: “Since the removal of pomalidomide from the CDF, Celgene has worked collaboratively with NICE to help ensure that patients in England can access this medicine which can improve overall survival by 5 months. The positive recommendation issued by NICE means that eligible patients across the UK can access this important treatment from today. This is great news for patients.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance